Long-Term Antidepressant Treatment: Let's Look at the Evidence-View Presentation Slides

View Presentation Slides

Pdf Summary

The "Long-Term Antidepressant Treatment: Let's Look at the Evidence" webinar, hosted by the American Psychiatric Association, aimed to explore the role of long-term antidepressant treatments in managing major depressive disorder (MDD). Presented by Dr. Thomas P. Hackett and Dr. Andrew A. Nierenberg, both esteemed psychiatrists, the session offered continuing education credits for physicians and provided an opportunity for attendees to engage in a Q&A segment.<br /><br />Key learning objectives included assessing the risk of recurrent depressive episodes, evaluating the effectiveness and limitations of long-term antidepressant treatments, and understanding the benefits and drawbacks of psychotherapy. Various antidepressants such as SSRIs, SNRIs, and other classes were discussed concerning their efficacy, with findings suggesting such treatments are twice as effective as placebos in preventing relapses. Psychosocial interventions were noted to be 1.4 times as effective as placebo.<br /><br />The discussion ventured into supplemental treatments like Vilazodone, Levomilnacipran, Vortioxetine, and newer methods, such as Esketamine and rTMS for relapse prevention. It also highlighted Brexanolone for postpartum depression and the role of Well-Being Therapy and online mindfulness-based CBT in maintaining recovery. The guideline for maintenance addressed frequent, severe, chronic, or difficult-to-treat episodes and the presence of comorbid conditions or residual symptoms.<br /><br />The presentation concluded with an invitation to upcoming webinars and instructions for claiming educational credits, encouraging a continued dialogue on the complex landscape of MDD management. Attendees were reminded of resources available through the SMI Adviser mobile app and invited to submit further inquiries to SMI experts.

Keywords

Long-term antidepressant treatment

Major depressive disorder

SSRIs

SNRIs

Psychotherapy

Relapse prevention

Esketamine

rTMS

Postpartum depression

Mindfulness-based CBT